103 related articles for article (PubMed ID: 38697166)
1. Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Tacchetti P; Talarico M; Barbato S; Pantani L; Mancuso K; Rizzello I; Zamagni E; Cavo M
Expert Rev Anticancer Ther; 2024 Jun; 24(6):379-395. PubMed ID: 38798125
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in multiple myeloma.
Asensi Cantó P; Arnao Herraiz M; de la Rubia Comos J
Med Clin (Barc); 2024 May; 162(10):485-493. PubMed ID: 38218655
[TBL] [Abstract][Full Text] [Related]
3. [Development of novel bispecific antibody therapy for multiple myeloma].
Konishi T; Ochi T; Takenaka K
Rinsho Ketsueki; 2024; 65(5):428-438. PubMed ID: 38825523
[TBL] [Abstract][Full Text] [Related]
4. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Raje NS; Cohen AD; Patel KK; van de Donk NWCJ; Richter J; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):350-357. PubMed ID: 38627181
[TBL] [Abstract][Full Text] [Related]
5. Current status of bispecific antibodies and CAR-T therapies in multiple myeloma.
Szlasa W; Dybko J
Int Immunopharmacol; 2024 Jun; 134():112043. PubMed ID: 38733817
[TBL] [Abstract][Full Text] [Related]
6. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma.
Mohan M; Van Oekelen O; Akhtar OS; Cohen A; Parekh S
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432204. PubMed ID: 38875506
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications.
Letouzé E; Moreau P; Munshi N; Samur M; Minvielle S; Touzeau C
Blood Adv; 2024 Jun; 8(11):2952-2959. PubMed ID: 38513088
[TBL] [Abstract][Full Text] [Related]
8. [Current status and future perspective of clinical trials for patients with multiple myeloma].
Suzuki T; Maruyama D
Rinsho Ketsueki; 2024; 65(5):420-427. PubMed ID: 38825522
[TBL] [Abstract][Full Text] [Related]
9. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.
Mo CC; Richardson E; Calabretta E; Corrado F; Kocoglu MH; Baron RM; Connors JM; Iacobelli M; Wei LJ; Rapoport AP; Díaz-Ricart M; Moraleda JM; Carlo-Stella C; Richardson PG
Blood Rev; 2024 Jul; 66():101218. PubMed ID: 38852017
[TBL] [Abstract][Full Text] [Related]
10. Risk of Infection in Patients With Multiple Myeloma Treated With T-Cell Redirecting Approaches: A Call Out for Clinicians.
Lupia T; Cani L; Bringhen S; De Rosa FG; Bruno B; Mikulska M; Corcione S; Mina R
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38849284
[TBL] [Abstract][Full Text] [Related]
11. Immune status and selection of patients for immunotherapy in myeloma: a proposal.
Dhodapkar MV
Blood Adv; 2024 May; 8(10):2424-2432. PubMed ID: 38564776
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic therapy: new actors in myeloma.
Solimando AG; Vacca A
Blood; 2024 Jun; 143(25):2564-2565. PubMed ID: 38900472
[No Abstract] [Full Text] [Related]
13. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.
Ludwig H; Munshi NC; Terpos E; Schweitzer I; Raje N; Moreau P; Nooka AK
Blood Adv; 2024 May; ():. PubMed ID: 38776433
[No Abstract] [Full Text] [Related]
14. Therapeutic Leap for Multiple Myeloma in 2015: Unprecedented FDA Drug Approvals.
Helwick C
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):36-9. PubMed ID: 27668043
[No Abstract] [Full Text] [Related]
15. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Rodriguez-Otero P; Usmani S; Cohen AD; van de Donk NWCJ; Leleu X; Gállego Pérez-Larraya J; Manier S; Nooka AK; Mateos MV; Einsele H; Minnema M; Cavo M; Derman BA; Puig N; Gay F; Ho PJ; Chng WJ; Kastritis E; Gahrton G; Weisel K; Nagarajan C; Schjesvold F; Mikhael J; Costa L; Raje NS; Zamagni E; Hájek R; Weinhold N; Yong K; Ye JC; Sidhana S; Merlini G; Martin T; Lin Y; Chari A; Popat R; Kaufman JL;
Lancet Oncol; 2024 May; 25(5):e205-e216. PubMed ID: 38697166
[TBL] [Abstract][Full Text] [Related]
16. SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.
Madduri D; Dhodapkar MV; Lonial S; Jagannath S; Cho HJ
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):537-544. PubMed ID: 31427259
[TBL] [Abstract][Full Text] [Related]
17. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
18. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond.
Su CT; Ye JC
J Hematol Oncol; 2021 Jul; 14(1):115. PubMed ID: 34301270
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
